Tutorial: Triheptanoin and Nutrition Management for Treatment of Long‐Chain Fatty Acid Oxidation Disorders. Issue 2 (11th November 2020)

• Record Type: Journal Article
• Authors: Norris, Marie K.; Scott, Anna I.; Sullivan, Sarah; Chang, Irene J.; Lam, Christina; Sun, Angela; Hahn, Sihoun; Thies, Jenny M.; Gunnarson, Melissa; McKean, Kelly N.; Merritt, J. Lawrence
• Is Part Of: JPEN, Journal of parenteral and enteral nutrition. Volume 45:Issue 2(2021)
• Page Start: 230
• Page End: 238
• Publication Date: 2020-11-11
• Subjects: anaplerotic -- carnitine‐acylcarnitine translocase deficiency -- fatty acid oxidation disorder -- medical nutrition therapy -- triheptanoin -- very long‐chain acyl‐CoA dehydrogenase deficiency; Parenteral feeding -- Periodicals; Enteral feeding -- Periodicals; 615.85484
• DOI: 10.1002/jpen.2034
• Languages: English
• ISSNs: 0148-6071

Abstract

Abstract: Background: Patients with severe long‐chain fatty acid oxidation disorders (LC‐FAODs) experience serious morbidity and mortality despite traditional dietary management including medium‐chain triglyceride (MCT)–supplemented, low‐fat diets. Triheptanoin is a triglyceride oil that is broken down to acetyl–coenzyme A (CoA) and propionyl‐CoA, which replenishes deficient tricarboxylic acid cycle intermediates. We report the complex medical and nutrition management of triheptanoin therapy initiated emergently for 3 patients with LC‐FAOD. Methods: Triheptanoin (Ultragenyx Pharmaceutical, Inc, Novato, CA, USA) was administered to 3 patients with LC‐FAOD on a compassionate‐use basis. Triheptanoin was mixed with non–MCT‐containing low‐fat formula. Patients were closely followed with regular cardiac and laboratory monitoring. Results: Cardiac ejection fraction normalized after triheptanoin initiation. Patients experienced fewer hospitalizations related to metabolic crises while on triheptanoin. Patient 1 has tolerated oral administration without difficulty since birth. Patients 2 and 3 experienced increased diarrhea. Recurrent breakdown of the silicone gastrostomy tube occurred in patient 3, whereas the polyurethane nasogastric tube for patient 2 remained intact. Patient 3 experiences recurrent episodes of elevated creatine kinase levels and muscle weakness associated with illness. Patient 3 had chronically elevated C10‐acylcarnitines while on MCT supplementation, which normalized after initiation of triheptanoin and discontinuation of MCT oil. Conclusions: Triheptanoin can ameliorate acute cardiomyopathy and increase survival in patients with severe LC‐FAOD. Substituting triheptanoin for traditional MCT‐based treatment improves clinical outcomes. MCT oil might be less effective in carnitine‐acylcarnitine translocase deficiency patients compared with other FAODs and needs further investigation.